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Maintenance of single-layered endothelium, squa-
mous endothelial cell shape, and formation of
a patent vascular lumen all require defined endothe-
lial cell polarity. Loss of b1 integrin (Itgb1) in nascent
endothelium leads to disruption of arterial endothe-
lial cell polarity and lumen formation. The loss of
polarity is manifested as cuboidal-shaped endothe-
lial cells with dysregulated levels and mislocalization
of normally polarized cell-cell adhesion molecules,
as well as decreased expression of the polarity
gene Par3 (pard3). b1 integrin and Par3 are both
localized to the endothelial layer, with preferential
expression of Par3 in arterial endothelium. Luminal
occlusion is also exclusively noted in arteries, and
is partially rescued by replacement of Par3 protein
in b1-deficient vessels. Combined, our findings
demonstrate that b1 integrin functions upstream of
Par3 as part of a molecular cascade required for
endothelial cell polarity and lumen formation.
INTRODUCTION
Essential to vascular morphogenesis, the molecular events that
regulate endothelial lumen formation have been difficult to
dissect. The information currently available has been gathered
from elegant in vitro studies in three-dimensional culture
systems that recapitulate the initial steps in the angiogenic
cascade. These in vitro studies have indicated that, at least in
capillary vessels, lumens result from the coalescence of vacu-
oles (Davis et al., 2007; Downs, 2003; Folkman and Haudens-Devechild, 1980). A similar process has also been observed in vivo,
as zebrafish intersomitic vessel sprouts demonstrate a required
alignment of vacuoles from preceding cells (Kamei et al., 2006).
The events are thought to be initiated downstream of integrin-
extracellular matrix signaling, and require the activation of
Cdc42, Rac1, pak2/4, Raf kinases, and the Par3/6/atypical
PKC complex (Koh et al., 2008, 2009). Further confirmation of
these regulatory mechanisms in vivo has been more difficult
to obtain, as these molecules are likely essential for multiple
functions, and studies using loss or gain of function would
require both temporal and cellular control. A more recent study
has demonstrated that in the early murine aorta, a two-cell
cord-like structure polarizes prior to downstream activation of
aPKC and Rho-associated proteins to form a lumen, in lieu of
vacuole accumulation (Strilic et al., 2009). Thus, themechanisms
of lumen formation may be as varied and specialized as the
vascular beds in which they occur.
The integrin family of heterodimeric transmembrane proteins
functions in cell-surface binding to extracellular matrix (ECM)
and simultaneous association with internal actin cytoskeletal
components (Hynes, 2002). These receptors are formed by pairs
of a and b subunits, and have been associated with processes
ranging from cell structure and adhesion to cell differentiation
and survival (Giancotti and Ruoslahti, 1999; Hynes, 2002). Of
the 22 currently recognized integrin heterodimers, at least seven
(avb3, avb5, avb1, a1b1, a2b1, a3b1, and a5b1) are expressed
by endothelial cells and have been implicated in vascular
morphogenesis (Hynes and Bader, 1997; Rupp and Little,
2001; Stupack and Cheresh, 2002). However, it has been chal-
lenging to ascertain their specific contributions during blood
vessel formation and homeostasis due to complex phenotypes,
functional overlap, and in some cases early embryonic lethality.
Because the b subunits associate with multiple a receptors,
genetic inactivation of specific b subunits is fruitful, as they result
in the lack of expression of multiple a-b pairs.lopmental Cell 18, 39–51, January 19, 2010 ª2010 Elsevier Inc. 39
Figure 1. Loss of b1 Integrin in the Endothelium
Results in Gene-Dose-Dependent Lethality
(A) VE-cadherin Cre deletion of b1 integrin gene in a hetero-
zygous null background (b1f/n; Cre+, blue) results in midg-
estational lethality, as compared to late fetal lethality in
homozygous floxed b1 integrin (b1f/f; Cre+, green). In
contrast, VE-cadherin Cre-mediated recombination of
exon 3 floxed alleles leads to a sharp lethality at E13.5
(b1e3/e3; Cre+, red).
(B) All deletions result in hemorrhaging (arrows) and
edema (arrowheads), as evidenced in whole-mount
embryos.
(C) Various b1 integrin deletion lines were evaluated at
E12.5 for the percentage of endothelial cells (ECs) that
expressed b1 integrin via FACS analysis. Percentages
are depicted in parentheses. Note that the mouse lines
with earlier lethality have a greater reduction in b1, and
the heterozygous b1 null (b1+/) has a background level
of 91%.
(D) Genetic deletion of the b1f/f; Cre+ line, as demon-
strated by b1 promoter-driven LacZ expression, shows
increasing endothelial deletion with advancing gestational
age.
(E) Endothelial cell b1 integrin protein expression, as
measured by FACS, depicts a lag in protein loss as
compared to genetic loss in (D). The bottom graph depicts
the percentage of endothelial population with b1 integrin
protein expression by FACS (b1f/f; Cre+ in green, b1f/+;
Cre+ in black).
All graphical data are shown as mean ± SEM with a
minimum of n = 3 per data set, except in (E), as data
sets of n = 2 do not depict error bars (E14.5 and E17.5).
Scale bars are as indicated. See also Figure S1.
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b1 Integrin and Endothelial PolarityThree recent reports using a Tie-2 Cre to ablate b1 integrin in
endothelial cells showed early lethality (embryonic day [E] 9.5–
E10.5), with defects in vessel patterning typified by reduction
in vascular branching frommain vessels, and sac-like structures
instead of uniform lumens (Carlson et al., 2008; Lei et al., 2008;
Tanjore et al., 2008). As the severity of the phenotype precludes
investigating the roles of b1 integrin in later angiogenic events,
we studied the function of b1 integrin in endothelial cells by
genetic inactivation using a VE-cadherin Cre (Alva et al., 2006).
The VE-cadherin Cre line initiates deletion as early as the Tie-2
Cre (E6.5), but full penetration is noted only by E14.5 (Alva
et al., 2006). The slower expression kinetics results in hypomor-
phic phenotypes and the possibility of investigating genetic
contributions at later stages of vascular maturation. Indeed,40 Developmental Cell 18, 39–51, January 19, 2010 ª2010 Elsevier Inc.deletion of b1 integrin using the VE-cadherin
Cre results in later lethality, and has uncovered
novel roles for this molecule in endothelial
cell polarity and subsequent downstream
events with far-reaching implications for lumen
formation.
RESULTS
b1 Integrin Loss Results
in Dose-Dependent Lethality
Cell-specific deletion of the Itgb1 gene (herein
called b1 integrin) with homozygous floxedalleles by VE-cadherin Cre recombinase (b1f/f; Cre+) results in
lethality that spans from E13.5 to E17.5 (Figure 1A, green).
When a floxed allele is replaced by a ‘‘null’’ allele (b1f/n; Cre+),
an earlier lethality is noted ranging from E10.5 to E14.5 (Fig-
ure 1A, blue). When inactivation of the b1 integrin gene is
confined to exon 3 (b1e3/e3; Cre+), a rather sharp lethality at
E13.5 is noted (Figure 1A, red). All deletions result in embryonic
death, and exhibit vascular rupture and hemorrhage (Figure 1B).
Whereas the impact of b1 integrin ablation is similar, the timing of
VE-cadherin Cre expression combined with efficiency of recom-
bination between floxed alleles of various sizes and numbers
results in a gene-dosage-dependent phenotype (Figure 1C).
Evaluation of b1 integrin protein expression within endothelial
cell (EC) populations at E12.5 of each mouse line shows that
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b1 Integrin and Endothelial Polarity85%of b1f/n; Cre+ ECs express b1 integrin, as compared to 89%
of b1e3/e3 (Figure 1C; see Figure S1F available online).
Cre-mediated inactivation can be traced when using the larger
floxed allele (b1f) by b-galactosidase (b-gal) staining, as a LacZ
reporter becomes in-frame upon gene excision (Figure 1D;
Figures S1A and S1D). Thus, b-gal indicates both the activity
of the b1 integrin promoter and the efficiency of recombination.
It is clear that by E14.5 a large majority of endothelial cells
have at least one allele recombined (Figure 1D; Figures S1A
and S1D). However, evaluation of protein expression shows
that b1-ablated endothelial populations comprise a small frac-
tion of the total at E15.5. In fact, even by E17.5, only 45% of
the endothelium shows complete loss of b1 integrin protein
(Figure 1E; Figure S1F). Therefore, genetic deletion may not
result in protein loss for quite some time, which in this case
provides a unique opportunity to evaluate b1 integrin ablation
in the context of late vascular development. The multiple models
of cell-specific deletion also allow for assessment of the b1 integ-
rin protein requirement in ECs. Significant lethality by E12.5 does
not occur until the b1 integrin protein expression within EC
populations drops below 89% (Figure 1C), suggesting that the
developing endothelium is exquisitely sensitive to b1 integrin
dosage. Evaluation of b3 integrin protein expression revealed
a proportional correlation between absence of b1 integrin and
increase of b3, indicating a potential compensatory mechanism
(Figures S1C and S1F).
b1 Integrin Is Critical for Lumen Formation
Detailed histological examination of viable endothelial specific
b1f/f; Cre+ mutants revealed frequent occlusion of mid-sized
vascular lumens (Figure 2; Figure S2A). By E14.5, the cells
occluding the lumen have undergone Cre-mediated b1 integrin
deletion, as evidenced by LacZ expression (Figure 2A), and
strongly express the endothelial adhesion protein PECAM-1 by
E15.5 (Figures 2A and 2B; Figure S2B). The observation of the
phenotype in medium-sized vessels and not larger arteries
may be attributed to the timing of complete deletion. The aorta,
other large-caliber arteries, and the endocardium display multi-
layered endothelium as well as cuboidal-shaped endothelial
cells (Figures 2D and 2E). The abnormal endothelial cell shape
is also noted in mouse lines with earlier lethality, b1f/n; Cre+
(Figure 2D) and b1e3/e3; Cre+ (Figure S1E), but at earlier time
points (E12.5). The effect is exclusive to cells that have total
loss of b1 integrin, as indicated by the b-gal staining in b1f/n;
Cre+ embryos (Figure 2D, arrows) and by b1 integrin immunos-
taining in b1f/f; Cre+ (Figure S3A, arrows). However, the full-
occlusion phenotype is most prominent at later developmental
stages (Figure S3C). Luminal occlusion and cuboidal endothelial
cell shape also occur after postnatal b1 integrin deletion with an
inducible system (Figure S2F). The data indicate that b1 integrin
is required for maintenance of endothelial cell shape, single-
layered morphology, and luminal patency of mid-sized arteries
after formation of the major vessels.
To examine whether the luminal occlusion was due to cell-
autonomous defects in the endothelium, we evaluated smooth
muscle cell morphology and function, ECM organization, and
thrombus formation. Smooth muscle cells are recruited to
b1-ablated vessels, but exhibit abnormal morphology and
smooth muscle actin organization (SMA) (Figure 2B, arrow-Deveheads). ECM deposition was noted to be disorganized (Fig-
ure S2C). These findings are likely due to aberrant patterning
originating from the primary endothelial defect, as deletion of b1
integrin within the smooth muscle cell compartment does not
result in luminal occlusion (Figure S2E). Luminal occlusion is
also not a result of thrombus formation, as exhibited by the pres-
ence of nucleated cells (ECs as per PECAM-1 expression) within
the lumen of mutant mice (Figure 3B; Figures S3A–S3C) and lack
of fibrinogen staining (Figure S2D). To examine whether
abnormal vascular smooth muscle tone could result in the ob-
served endothelial phenotype, animals were perfused with mus-
cle relaxants. The resultant effect was persistence of luminal
occlusionandcircumferential distributionofPECAM-1 (Figure2C).
Loss of b1 Integrin Affects Arterial Endothelial Cell
Polarity through Par3
To understand the molecular mechanisms underlying the
observed phenotype, we performed microarray analysis and
compared endothelial cells lacking b1 integrin (b1f/f; Cre+) with
ECs from the same mice that still expressed b1 integrin
(Figure S1G) at E16.5. A clear pattern emerged in which cell-
cell and cell-matrix adhesion proteins were increased and, in
accordance with the FACS data, b1 integrin transcripts were
decreased while b3 transcripts were increased (Figure 3A).
These findings were reproduced by qRT-PCR (Figure S3D). b1
integrin protein loss was also confirmed in ablated vessels by
immunohistochemistry (IHC) (Figure 3B; Figures S3A–S3C),
and within the FACS-sorted population by western blotting
(Figure 3C).
An unexpected consequence of b1 integrin deletion was
a reduction in transcripts coding for the polarity protein Par3
(Figure 3A). Par3 is a well-known polarity regulator that functions
in a complex with aPKC and Par6 in epithelial cells (Suzuki and
Ohno, 2006). Interestingly enough, other members of the com-
plex were not transcriptionally affected by b1 integrin deletion
as per our microarray and qRT-PCR analyses (Figure S3D,
legend). However, Par6 and aPKC have been shown to interact
independently of Par3 (Yamanaka et al., 2003). We also con-
firmed that the transcriptional decrease in Par3 translated to
loss of protein in b1 integrin-ablated EC populations by western
blot (Figure 3C).
Further investigation of specific cell-cell adhesion proteins in
mutant mice demonstrated abnormalities in localization
(Figure 3D). VE-cadherin, which is restricted to lateral cell-cell
borders of luminized vessels (Figure 3D, arrows), was broadly
redistributed in the absence of b1 integrin and present around
the entire cell perimeter (Figure 3D, arrows). Another polarized
protein, CD99, noted to be localized to cell junctions and have
distal expression to PECAM-1 (Schenkel et al., 2002), was also
mislocalized (Figure 3D, arrowheads). In the absence of b1 integ-
rin, CD99 was found all around the cell and was colocalized with
PECAM-1 at these sites (Figure 3D, arrows). PECAM-1 was also
notably increased and relocated to circumscribe the entire cell
perimeter (Figures 3B and 3D, arrows). Podocalyxin, an apical
marker of endothelium (Meder et al., 2005), was also noted
to lose its specialized luminal localization in the absence of b1
integrin (Figure S3B). b1 integrin was predominantly found on
the basal aspect of the arterial endothelial cell membrane,
and was absent in the b1f/f; Cre+ animal (Figures 3B and 3J;lopmental Cell 18, 39–51, January 19, 2010 ª2010 Elsevier Inc. 41
Figure 2. b1 Integrin Endothelial Deletion Results in Luminal Occlusion, Cuboidal Cell Shape, and Stratification of the Endothelial Layer
(A) b-gal staining identifies b1-deleted endothelial cells (top panel) surrounding a nearly occluded lumen (arrow) in the E14.5 homozygous floxed (b1f/f; Cre+)
animal. PECAM-1 (bottom, black) also demonstrates an occluded endothelial lumen (arrow) at E15.5. Note that vessels appear occluded by endothelial cells
(PECAM-1+), as also demonstrated in (B) (arrows). Panels are histological sections of skin with either b-gal (blue) or PECAM-1 (black), and nuclear stain in red.
(B) Occlusion of the lumen was demonstrated in semithin sections of E15.5 b1f/f; Cre+ mice (arrows; top panel), and again with PECAM-1 expression (arrows;
PECAM-1 in red). Endothelial deletion of b1 integrin also leads to abnormalities of smooth muscle cell (SMC) organization. Whereas SMC morphology appears
near normal in the semithin sections (arrowheads), a smooth muscle actin staining (SMA; green) depicts disorganization within SMC layers (arrowheads).
(C) To ensure the occluded lumens were not a function of vascular constriction, muscle relaxants were administered to pregnant dams prior to sacrifice, and
sections demonstrate no change in the occlusion phenotype (arrow). PECAM-1, black; nuclear stain, red.
(D) b1 integrin loss is associated with atypical cuboidal shape (black arrows) and stratification (brackets and white arrows) in contrast to the normally flattened
appearance of other adjacent endothelial cells (arrowheads). Top panels: E12.5 b1f/n; Cre+ endocardial cells exhibit b1-LacZ expression (b-gal staining in blue)
after Cre-mediated excision (counterstain in red or hematoxylin and eosin staining in purple). b1 integrin-ablated embryos also exhibit single-layered squamous-
shaped endothelial cells (arrowheads) within the same section of cuboidal ECs or stratification, suggesting that full deletion does not occur within the entire
endothelial population simultaneously. Lower panels: stratification is also seen in E16.5 b1f/f; Cre+ (arrows) large-vessel endothelium (PECAM-1, red; SMA,
green).
Developmental Cell
b1 Integrin and Endothelial Polarity
42 Developmental Cell 18, 39–51, January 19, 2010 ª2010 Elsevier Inc.
Developmental Cell
b1 Integrin and Endothelial PolarityFigures S3A–S3C). In hybrid vessels composed of b1-positive
and b1-negative ECs, the mislocalizaton of PECAM-1 was
confined to b1-negative cells (Figure S3A). The data indicate a
strict regulatory relationship between cell-matrix and cell-cell
adhesion molecules. In addition to luminal occlusion, stratifica-
tion, and misorientation of polarized adhesion molecules, loss
of b1 integrin also demonstrated endothelial cyst-like structures
in larger vessels (Figure S4G).
Whereas luminal occlusion was found in medium- and small-
sized arteries, it was not evident in veins, capillaries, or
lymphatics, even though b1 integrin is expressed in all vessel
types (Figures 3E and 3F; Figure S4F). When luminal patency
was quantified according to vessel type, it became readily
apparent that the occlusion phenotype was strictly arterial
(Figure 3G). When Par3 localization was evaluated by IHC, it
also exhibited a preferential arterial expression (Figure 3H).
Par3 was predominantly found in the basal aspect of arterial
endothelial cells, and there it colocalizes with b1 integrin (Figures
3Ha and 3Hb, arrows). However, it is also expressed within the
smooth muscle cell layer and to some extent in veins (Figures
3Ha and 3Hb, arrowheads; Figure 3Hc, arrows). To verify
whether there was increased Par3 expression within the arterial
compartment, aortas and vena cavas from wild-type mice were
flushed with Laemmli buffer to enrich for endothelial protein and
evaluated for Par3 protein by western blot (Figure 3I). Increased
expression of all Par3 isoforms was noted within the arterial
compartment, but especially the 150 kDa isoform. These differ-
ences were only found in young (4-week-old) animals (Figure 3I).
Par3 protein expression was also examined across cell lysates
from primary human endothelial cell lines of arterial (HAEC),
umbilical vein (HUVEC), and saphenous vein (HSVEC) origin
(Figure 3I). There were no differences between endothelial cell
types in culture, but the human EC lines did demonstrate
a distinct Par3 isoform pattern as compared to mouse vessels.
In b1 integrin-ablated vessels, Par3 was no longer basally local-
ized but instead aggregated at cell borders (Figure 3J, arrows).
In addition, recombined cells occluding the lumen no longer
expressed either b1 integrin or Par3 (Figure 3J, arrowheads).
This was noted to a larger extent in older embryos (Figure S3C),
suggesting that Par3 is mislocalized prior to its decrease in
expression.
Postnatal b1 Integrin Ablation Results in Reduction
of Par3 in the Retinal Vasculature
By using a tamoxifen-inducible VE-cadherin Cre line, we were
able to impose Cre-mediated ablation of b1 integrin in the post-
natal retinal vasculature. Recombination was assessed by either
b-gal staining or EYFP expression from the ROSA26 locus
(R26R) Cre reporter (Soriano, 1999). Western blots for Par3 of
wild-type whole retinal lysates showed an early peak between
postnatal day 3 (P3) and P6 (Figure S4A). However, as there exist
multiple cell types in the retina that likely express Par3, endothe-
lial cells were isolated and further analyzed (Figures S4B and
S4E). Interestingly, the retinal endothelial cells demonstrate
a different developmental expression pattern for Par3, with(E) Altered cell shape at the ultrastructural level (arrows) is seen at E15.5 (b1f/f; C
(arrowheads).
Scale bars are labeled for each row. See also Figure S2.
Devea peak at P9, which coincides with a period of intense retinal
vascular remodeling (Figure 4A). In retinal sections, Par3 is
clearly expressed in the endothelium (Figure 4B).
Postnatal b1 ablation resulted in discrete hemorrhagic sites in
the retina (Figure S4C), endothelial cell clumping, and cyst-like
outgrowths (Figures 4C and 4F; Figure S4D), phenotypes that
resemble those found in the embryo (Figure S4G). Upon cross-
sectioning, luminal occlusion was also observed in the retina
as a result of b1 ablation (see below). However, the inducible
system was notably less robust when compared to the constitu-
tive VE-cadherin Cre, as evidenced by LacZ activity from the
R26R locus (Figure 4D). Nonetheless, when Par3 protein was
evaluated in b1 integrin-ablated retinal endothelial cells, a
decrease in Par3 protein was detected in lysates that also
demonstrated Cre expression and loss of b1 integrin (Figure 4E).
To ensure that the abnormalities were due to b1 integrin loss, we
further evaluated b1 IHC in conjunction with an EYFP R26R line,
thus labeling cells that underwent Cre recombination. As noted
in Figure 4F, cells that undergo deletion (EYFP+; green) are
abnormally situated in the vasculature (isolectinB4; red) and
lack b1 integrin expression (blue). Therefore, the postnatal retinal
model recapitulates the findings of embryonic b1 integrin dele-
tion in the embryo.
Pharmacological Blockade of b1 Integrin in the Retina
To further confirm the role of b1 integrin in vascular morphogen-
esis, we induced global b1 integrin pharmacological blockade
in postnatal (P4, P7, and adult) retinas and evaluated the
vasculature 72 hr later. The blockade at P7 mimics the inducible
b1 integrin ablation with abnormal cell aggregation and luminal
occlusion (Figures 5A and 5B), but also demonstrates more
severe effects with excess branching (Figure 5A). To evaluate
whether pericyte coverage was affected, we investigated NG2
expression (Figure 5B, green) and noted that whereas there
was a lack of coverage in abnormally located ECs (Figure 5B,
arrows), the majority of vessels had NG2+ pericyte coverage
equivalent to controls.
We also investigated whether arterial identity was affected, as
the increased branching and loss of arterial-venous borders may
suggest. Dll4, a Notch ligand known to be specific for arterial
identity (Shutter et al., 2000), was evaluated. Even though the
arteries exhibited increased branching and loss of the avascular
zone surrounding the main arterial vessel, the expression of Dll4
was intact in arteries (Figure 5C). To understand the requirement
of b1 integrin earlier in angiogenesis, and in quiescent vessels,
pharmacological b1 integrin blockade was conducted at P4,
a very early stage of retinal angiogenesis, and in the adult. Earlier
blockade also appeared to demonstrate branching abnormali-
ties and EC aggregates with luminal occlusion (Figure 5D), but
there were also pericyte abnormalities in which NG2+ pericytes
appeared to be increased in number (Figure 5D). As the P4
time point precedes the peak of retinal angiogenesis, it is likely
the blockade also affects other populations that participate in
vascular retinal patterning. In contrast, adult retinal inactivation
of b1 integrin leads to very few consequential effects. Rarely,re+), alongside normally shaped endothelial cells comprising the vessel wall
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Figure 3. Luminal Occlusion and Loss of Polarity Are Arterial Phenomena
(A) Microarray analysis of endothelial cells (ECs), sorted based on b1 integrin protein expression (from E16.5 b1f/f; Cre+ embryos), exhibited increased levels of
adhesion-related genes and a decrease in the polarity gene Par3.
(B) Loss of b1 integrin protein (green) results in mislocalization of PECAM-1 (red) from laterally placed cell-cell contacts to global cell-surface expression (arrows).
TOPRO-3 nuclear stain is in blue.
(C) To confirm the loss of b1 integrin and Par3 on a protein level, ECs sorted in the samemanner were evaluated bywestern blot. Sorted b1+ and b1 endothelial cells
fromb1f/f; Cre+miceandb1+ECs fromb1f/+; Cre+micewere loadedequally by cell number, anddemonstrated loss ofb1andPar3protein (a-enolase loading control).
(D) Normally polarized expression of VE-cadherin (top panel in red; SMA in green) at lateral cell-cell contacts (arrows) is dispersed and circumferentially expressed
in cells occluding the lumen within b1f/f; Cre+ vessels (arrows). CD99 (bottom panels; green) demonstrates a polarized apical expression (arrowheads) and lateral
colocalization with PECAM-1 (yellow; arrows) that after b1 integrin ablation redistributes to surround the cell at E15.5 (arrows), much like PECAM-1 (in red).
(E) Luminal occlusion is distinctly noted in arteries (arrows), as delineated by PECAM-1 (top panels in black; bottom panels in red) and lack of EphB4 (bottom
panels; green) expression. A, arteries; V, veins; L, lymphatics.
(F) The extent of occlusion can vary in mid-sized arteries (arrows) at E15.5 after endothelial b1 integrin deletion, but as compared to nearby veins is a distinctly
arterial phenomenon. Lower panels are high magnification of vessels in upper panels. PECAM-1 is in black.
(G) Vessels were evaluated at E15.5, quantified for luminal patency, and confirmed that the phenotype is exclusively arterial (n = 5 each; *p < .001).
(H) Par3 protein expression is preferentially expressed in embryonic arteries, as evidenced in b1f/f; Cre at E15.5 (Par3, red; b1 integrin, green; TOPRO-3 nuclear
stain, blue). (a)–(c) are higher magnifications of the arterial-venous pair above. (a and b) Par3 colocalizes with b1 integrin (yellow) in the basal aspect of the arterial
endothelial layer (arrows), but is also prominent in the surrounding smooth muscle cell layer (red; arrowheads). (c) Veins also express Par3 in conjunction with b1
(yellow; arrows), but to a lesser extent than arterial vessels.
(I) To evaluate Par3 expression in vessel subtypes, dorsal aortas (A) and inferior vena cavas (V) of 4-week-old and adult animals were flushed with Laemmli buffer
and evaluated by western blot. Primary human endothelial cells were evaluated for Par3 expression among vessel subtypes (human aortic endothelial cells,
HAECs; human umbilical vein ECs, HUVECs; human saphenous vein ECs, HSVECs). GAPDH and a-enolase loading controls.
(J) Normal basal expression of Par3 (red) with coexpression of b1 integrin (green; colocalization in yellow) in b1f/f; Cre vessels (arrows) is aggregated and
mislocalized in b1f/f; Cre+ vessels (arrows), with complete absence in b1-deleted cells within the vessel lumen (arrowheads). TOPRO-3 nuclear stain is in blue.
Scale bars are labeled for each row. See also Figure S3.
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majority of adult vessels, both morphology and pericyte
coverage were undisturbed, suggesting that vascular b1 integrin
may be most critical in the angiogenic stages following the prim-
itive plexus, but prior to vessel quiescence.
As we observed an increase of b3 integrin in the absence of b1
integrin (Figures S1C and S1F), the retinal model allowed us to
investigate whether this upregulation had a protective or detri-
mental effect on vascular development. When b3 integrin
blockade was induced in the postnatal retina, the retinas
exhibited defects in vessel patterning with an inability to prog-
ress past the primitive plexus stage and defects in pericyte
coverage (Figure S5). If b3 and b1 integrins were both pharmaco-
logically blocked, the phenotype resulted in a combination of the
individual phenotypes observed: EC aggregates, persistence
of a primitive vascular pattern, and loss of pericyte coverage
(Figure S5).
Viral-Mediated Par3 Delivery Partially Rescues Luminal
Defects Imposed by b1 Integrin Deletion
When retinal endothelial cells undergo b1 integrin deletion, the
phenotype of luminal occlusion and cell aggregates was partially
rescued by delivery of Par3 (Figure 6). Ocular lentiviral delivery of
Par3 driven by a CMV promoter (Sfakianos et al., 2007) rescued
the occlusion phenotype by almost 40% (p = .025) when retinal
vessels were evaluated for patency in the context of the deletion
background (Figures 6C and 6D). The extent of deletion was
normalized after b-gal staining of endothelial cells within sepa-
rate vascular beds, and was noted to be comparable between
lentiviral empty vector control and Par3 rescue (Figures 6D and
6E). To ensure that the normalization of vessel morphology
was specifically due to viral rescue, we developed a triple-flag-
tagged Par3 lentivirus under the control of a VE-cadherin
promoter (Figure S6), and rescued postnatal animals crossed
to the EYFP R26R Cre reporter. Using this strategy, we were
able to track virally rescued b1 integrin-ablated ECs within the
retinal vasculature (Figure 6B). Deleted ECs that were not
rescued retained their abnormal shape and morphology,
whereas rescued ECs reverted back to a normal phenotype
(Figure 6B).
Lumen Formation Is Halted with Accumulation
of Intracellular Vacuoles
A final aspect of the vascular occlusion phenotype is that the ECs
occluding the lumen exhibited an overaccumulation of vacuoles
within their cytoplasm (Figure 7A). This accumulation is not likely
due to cell death, as there were no observed changes in cleaved
caspase-3 activity (data not shown) and the cells did not exhibit
hallmarks of apoptosis by electron microscopy. However, the
increase in vacuole number may be either the cause or conse-
quence of increased Rab7 transcripts found upon b1 genetic
ablation (Figure 3A). As Rab7 is noted in late-stage vacuole
formation (Stenmark, 2009), the data may suggest that vacuole
maturation is not arrested but vacuole fusion may be. When
Rab7 protein is evaluated at late embryonic stages of b1 integrin
deletion (E17.5), there is definitive increases of Rab7 in nonpolar-
ized ECs that have lost b1 integrin (Figure 7B). As directed
vacuole formation and fusion is one method of lumen formation
(Iruela-Arispe and Davis, 2009), it may be that arrest of lumenDeveformation due to b1 integrin deletion, and subsequent loss of
polarity, results in abnormal vacuole accumulation. In addition,
loss of b1 integrin also demonstrated endothelial cyst-like struc-
tures in larger vessels and the retina (Figure S4G; Figures 4C, 4F,
and 5B). The cysts may also be a result of intracellular vacuole
accumulation, and possibly associated with the observed
increase of Rab7 (Figure 3A).
DISCUSSION
Our investigation defines an overarching sequence of events
that begins initially with a loss of endothelial cell polarity as
a result of b1 integrin ablation. Once cell polarity is lost, the
mechanisms that maintain a single endothelial layer, as well
as the formation of a patent lumen, are also lost. Arrest of lumen
formation can also be seen with b1 integrin pharmacological
blockade, both in the avian embryo (Drake et al., 1992) and
the postnatal retina (Figure 5). Endothelial deletion of b1 integrin
results in substantial increases and ubiquitous localization of
cell-cell adhesion proteins Claudin-5, PECAM-1, VE-cadherin,
and CD99 (Figure 3). This resembles patterns of abnormal
lumen formation in Drosophila heart tubes, where gain-of-func-
tion E-cadherin mutants display increased cell adhesion and
subsequent loss of luminization (Santiago-Martinez et al.,
2008). The data presented here suggest that at least within
the endothelium, VE-cadherin and other cell-cell adhesion
molecules operate downstream of cell-matrix cues and internal
cell-polarity cues (Par3) to set up ordered polarized cell-cell
contacts.
In models of in vitro endothelial lumen formation, events are
initiated downstream of integrin-extracellular matrix signaling,
but also require the activation of Cdc42, Rac1, Pak2/4, and
the Par3/6/aPKC complex (Koh et al., 2008). Although we did
not examine Cdc42 or other Rho-family GTPases, the genetic
deletion of b1 integrin may affect its ability to activate Cdc42.
Yet, our data also suggest a genetic link between b1 integrin
and Par3, as ablation of b1 integrin results in loss of Par3.
Another contrast to the in vitro data is that while lumen formation
of mid-sized arteries was blocked upon b1 integrin endothelial
ablation, lumens of single-cell capillaries were unaffected. An
initial conclusion is that much like epithelial cells (Lubarsky
and Krasnow, 2003), lumen formation in vessels of distinct
type and caliber is likely to employ alternative processes or
molecules.
Recent data in epithelial tube formation suggest that there are
Cdc42-independent mechanisms in forming a patent lumen, and
that separate and distinct polarity complexes can function as
polarity regulators: the association of Cdc42 with polarity
complex members Par6 and aPKC being one complex and
separately, Par3 localized to tight junctions being another (Jaffe
et al., 2008; Martin-Belmonte et al., 2007). Par6 and aPKC have
been shown to interact independently of Par3 (Yamanaka et al.,
2003). This divergent set of events fits nicely with our data, as we
did not observe any transcriptional changes in other polarity
complex members, Par6 and aPKC included (Figure S3D and
data not shown). Specific to endothelium, Par3 can associate
with VE-cadherin in the absence of aPKC and prior to the
association of Par6 (Iden et al., 2006). Thus, it may be that cell-
cell and cell-matrix contacts operate separately in maintaininglopmental Cell 18, 39–51, January 19, 2010 ª2010 Elsevier Inc. 45
Figure 4. Postnatal Retinal b1 Integrin Deletion Results in Par3 Loss and Abnormal Endothelial Cell Polarity
(A) Wild-type (WT) retinal endothelial cell protein evaluated by western blot demonstrates that Par3 levels peak at P6–P9.
(B) Par3 (red) is expressed in WT retinal vessels (P10) with b1 integrin (green; arrows). TOPRO-3 nuclear stain is in blue.
(C) Postnatal b1 integrin ablation induced by tamoxifen injection (from P2 to P7) in the b1f/n; iCre+ retina results in large cyst-like outgrowths from the vasculature
at P9 (arrows in right panel). Isolectin B4 (IsoB4) is in red.
(D) Postnatal tamoxifen induction when traced using a LacZ R26R Cre reporter line (R26R; iCre+) labels a small subset of retinal endothelia at P7, as compared
to constitutive expression (R26R; Cre+). A, arteries; V, veins.
(E) After postnatal induction, retinal endothelial cells were isolated (at P9) and evaluated by western blot. b1 integrin protein is notably decreased in b1f/n; iCre+,
as are Par3 protein levels (right column).
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b1 Integrin and Endothelial Polaritycell polarity through convergent pathways, where both cadher-
ins and integrins are capable of activating Cdc42 pathways
(Desai et al., 2009; Koh et al., 2008) or alternatively regulating
polarity proteins. In our study, cell-matrix cues (via b1 integrin)
appear to exert initial and critical control of cell-cell adhesion
protein distribution and the polarity protein Par3.
In epithelial cells, successful lumen formation requires
directed centripetal vacuole movement toward the future lumen
and eventual coalescence with the plasma membrane. When b1
integrin is deleted, endothelial cells are no longer polarized, and
thus may become incapable of directed vacuole movement and
fusion, leading to the retention of vacuoles. This is a likely cause
or consequence of the increase in Rab7, a Rab GTPase that may
prove critical to endothelial vacuole trafficking, analogous to
other Rabs during epithelial lumen formation (Desclozeaux
et al., 2008). Whereas the downstream mechanisms of lumen
formation (vacuole formation and fusion) are employed in b1
integrin-ablated vessels, the phenotype is restricted to arterial
endothelial cells. It is well known that subspecification within
endothelial lineages includes identity markers for each endothe-
lial subtype. Our study demonstrates that in addition to canonical
arterial markers such as Dll4, Par3 (especially isoform 150 kDa) is
preferentially expressed in nascent arterial vessels. However,
the Par3 protein increase and isoform pattern in arteries is
fleeting, and eventually becomes nonexistent in the adult. The
significance of specific Par3 isoform expression is unclear, but
differences in isoform binding abilities have been previously
shown (Sfakianos et al., 2007). It is likely that arteries activate
a specific and exclusive set of events for lumen formation that
are then silenced after successful patency.
The downstream consequence of vascular b1 integrin abla-
tion, as dissected in this study, lends mechanistic insight into
the process of polarity maintenance and lumen formation in
arterial endothelium. The first and main cause of these subse-
quent events appears to be loss of Par3 and thus cell polarity,
which includes abnormal distribution of cell-cell adhesion mole-
cules. As a result, the endothelial cells adopt atypical cell shapes
and increase their adhesive properties. Although intracellular
vacuoles appear capable of forming in lieu of b1 integrin, they
are no longer capable of directed migration and coalescence
to form a lumen. However, lumen formation is restored with
the addition of Par3 protein, suggesting that the adhesion
changes and lumen defects are downstream of polarity cues,
which are regulated by cell-matrix interactions via b1 integrin
(Figure 7C).EXPERIMENTAL PROCEDURES
Animals
Mouse lines (and their respective genotyping) VE-cadherin Cre (Alva et al.,
2006), inducible VE-cadherin Cre (Monvoisin et al., 2006), floxed b1 integrin
exons 2–7 (Potocnik et al., 2000), floxed b1 integrin exon 3 (Raghavan et al.,
2000), b1 integrin null (Stephens et al., 1995), R26R LacZ (Soriano, 1999),
and R26R EYFP (Srinivas et al., 2001), as described, were maintained in the
Animal Research Facility at the University of California, Los Angeles. Care
and experimental procedures were performed in accordance with university(F)When b1f/n; iCre+ crossed to an EYFPR26R reporter undergoes b1 ablation, the
the vasculature in cyst-like structures (labeled by IsoB4 in red) and demonstrate
Scale bars are included for each row. See also Figure S4.
Deveguidelines. Pregnancies were dated by the presence of a vaginal plug
(day 0.5 of gestation). For survival data, 673 embryos were evaluated for the
b1f/f deletion, 104 embryos for the b1e3/e3 deletion, and 234 embryos for the
b1f/n deletion.
Immunohistochemistry
Littermate controls were used throughout the study. Immunostaining and
b-galactosidase protocols were as previously described (Alva et al., 2006;
Monvoisin et al., 2006). Electron microscopy was as previously described
(Lee et al., 2007).
Tissue sections underwent immunostaining with the following antibodies:
PECAM-1 1:100 (BD Pharmingen), fibrinogen 1:100 (Abcam), incubation with
biotinylated secondary antibodies, Vectastain ABC kit, DAB substrate, and
nuclear fast red counterstain (all from Vector Laboratories). Separately, tissue
sections also underwent the Tyramide signal amplification system with Alexa
Fluor secondary antibodies (Invitrogen) per the manufacturer’s instructions
with b1 integrin 1:500 (Chemicon), PECAM-1 1:500 (raised in rabbit; a generous
gift from Josephine Enciso and Joseph Madri, Yale University), Par3 1:300
(Upstate Biotechnology), Rab7 1:500 (Cell Signaling), and TOPRO-3 (Invitro-
gen) nuclear stain. Retina whole-mount staining was done using Alexa Fluor-
conjugated isolectin IB4 1:100 (Invitrogen) and NG2 1:100 (Chemicon) as
described (Hellstrom et al., 2007), and anti-FLAG M2 1:100 (Sigma) using
the M.O.M. kit (Vector), with Alexa Fluor-conjugated secondary antibodies
(Invitrogen).
Alternatively, for vibratome sections (250 mm), the following primary
antibodies were used: PECAM-1 1:500 (BD Pharmingen), paxillin 1:100 (BD
Pharmingen), laminin 1:200 (Sigma), a-smooth muscle actin FITC-labeled
1:500 (Sigma Laboratories), CD99 1:100 (from Gabriele Bixel, Max Planck
Institute), Texas red X phalloidin 3.5:100 (Molecular Probes), b1 integrin
1:100 (Chemicon), Claudin-5 1:100 (Zymed); EphB4 1:100 (R&D Sytems),
and VE-cadherin 1:150 (BV 13/4; a generous gift of ImClone Systems). Primary
antibodies were revealed with the appropriate secondary antibodies conju-
gated with either FITC or Cy3 (Jackson ImmunoResearch Laboratories). All
fluorescent IHC was analyzed using a Bio-Rad confocal MRC1024 or a Zeiss
LSM multiphoton microscope.
FACS Analysis and Antibodies
Embryos (or retinas) were mechanically dissociated by collagenase digestion
(Sigma), followed by red cell lysis, and filtered (70 mm and 40 mm). Cells were
incubated with PE-conjugated PECAM-1, FITC-conjugated b1 integrin, biotin-
conjugated b3 integrin with streptavidin-Tricolor, and APC-conjugated CD45
antibodies and analyzed on a FACSCaliber with the appropriate isotype
controls. Antibodies and isotype controls were purchased from BD Pharmin-
gen; streptavidin-Tricolor was from Caltag/Invitrogen.
Cell Sorting and Microarrays
FACSAria-sorted endothelial cells from b1f/f; Cre+ whole embryos at E16.5
were gated for PECAM+/CD45 and further sorted on b1 integrin protein
expression. Approximately 2–4 mg of purified RNA was converted into
double-stranded cDNA (Superscript; Invitrogen). Four hundred nanograms
of biotin-labeled cRNA was synthesized from cDNA using an IVT labeling kit
(Affimetrix). Affymetrix GeneChip Fluidics Station 400 hybridized fragmented
biotinylated cRNA to the Affymetrix Mouse Expression Set 430 ChipA Gene-
Chip array (over 14,000 full-length annotated mouse genes and nearly 4,000
expressed sequence tags). Arrays were stained and scanned using a Hew-
lett-Packard GeneArray scanner. Comparisons were performed between
b1f/f; Cre+ ECs that were b1+ and b1 using a total of six Affymetrix Gene-
Chips. Data generated following probe hybridization were analyzed with
Microarray Suite 5.0 (Affymetrix). Array images were visually examined for
array or probe hybridization abnormalities.
Smooth Muscle Relaxation
Pregnant dams were anesthetized and perfused at 120 mmHg with 10 mg/ml
adenosine (Sigma), 4 mg/ml papaverine (Sigma), and 10 U heparin/ml inb1-deleted retinal ECs (EYFP+ in green; arrows) become abnormally located in
loss of b1 protein (blue).
lopmental Cell 18, 39–51, January 19, 2010 ª2010 Elsevier Inc. 47
Figure 5. b1 Integrin Antibody Blockade Recapitulates the Genetic Deletion Phenotype
(A) b1 integrin pharmacological blockade at P7 and evaluation at P10 demonstrate increased endothelial cell aggregation and cysts (arrows) with increased
branching and decreased borders between arteries (A) and veins (V). Note the normally avascular area surrounding the retinal arteries is restricted after b1
antibody blockade (arrowheads). Isolectin B4 (IsoB4) is in red.
(B) Top panel: the cysts are composed of endothelial cells, as demonstrated by IsoB4 and TOPRO-3 (blue) nuclear staining (arrows). Bottom panels: when retinas
are evaluated for pericyte coverage (NG2; green), there is no observed effect after b1 blockade; however, ECs that are abnormally positioned with respect to the
vasculature, or in cysts, are not covered by pericytes (arrows). PECAM-1 staining (brown) of histological sections demonstrates abnormal vessel morphology
(arrows) and luminal occlusion (inset).
(C) Dll4, an arterial marker (green), was examined to evaluate whether arterial identity was affected as a result of b1 antibody blockade. Whereas Dll4 expression
was preserved (arrowheads), increased branching with closer proximity to the main arterial vessel is apparent (arrows, brackets).
(D) To evaluate the effects of b1 blockade at different ages, retinas were injected either at P4 or in the adult and evaluated 72 hr later. Left: the P4 blockade results
in abnormal vascular patterning (IsoB4 in red) with excessive pericyte coverage (NG2 in green), and luminal occlusion (PECAM-1 in brown; arrows). Right: in the
adult, very few abnormalities were encountered. Rarely, small cysts could be seen (IsoB4 in red; inset) as well as modest thickening of the endothelial layer
(PECAM-1 in brown; arrow), whereas pericyte coverage was normal. TOPRO-3 nuclear stain is in blue.
Scale bars are shown for each row. See also Figure S5.
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PFA followed, and the embryos were removed and processed as described
above.48 Developmental Cell 18, 39–51, January 19, 2010 ª2010 Elsevier InOcclusion Counts
Littermates at E15.5 were genotyped and stained with PECAM-1. Skin
sections 5 mm thick from embryos were evaluated 100 mm apart for thec.
Figure 6. Par3 Partially Rescues Lumen Occlusion and Cyst Formation in Endothelial b1 Integrin Ablation
Postnatal animals (b1f/n; iCre+) were induced with tamoxifen (P2–P7) and retinal vasculature was evaluated from P9 to P12. A subset was then rescued with Par3
lentiviral ocular delivery 48 hr prior to evaluation.
(A) The large cysts observed with postnatal b1 integrin ablation were resolved significantly with lentiviral Par3 replacement, but a few endothelial cells still
displayed smaller atypical aggregates (arrows). Isolectin B4 (IsoB4) is in red.
(B) When b1f/n; iCre+ crossed to EYFP R26R (green) retinas were rescued with FLAG-tagged Par3 lentivirus (blue), a rescued vessel demonstrates a patent lumen
(arrowheads). In contrast, ECs that underwent b1 deletion (green) but were not rescued remain abnormally shaped with an occluded lumen (arrows). Asterisk
denotes a EYFP+ red blood cell.
(C) On analysis of retinal semithin sections, b1 ablation resulted in vessel occlusion (arrowheads) that was partially rescued with Par3 protein (arrows). Boxed
areas are magnified on the right.
(D) Retinal vessels were quantified for the percentage of deletion (left) by assessing b-gal-positive endothelial cells within the abdominal muscle; tamoxifen group
(dark gray) and tamoxifen + Par3 rescue group (light gray). The number of occluded vessels was quantified and compared to percent deletion in a ratio (right). The
b1f/n; iCre+ tamoxifen group (dark gray) demonstrates that the occlusion phenotype is in direct proportion to the amount of deletion. There is a significant (*)
decrease in the ratio of occluded vessels (%) to percent deletion with Par3 rescue (light gray). Data are shown as mean ± SEM; n = 7 each group; p = 0.025.
(E) On a per-animal basis, the percentage of deletion varies (circles) but averages at approximately 30% for both groups, whereas the percentage of occlusion
(triangles) is dramatically reduced from 27% in the nonrescue to 16% in the rescued group.
(F) Higher magnification depicting the vessel occlusion (or patency in the rescue) that was quantified in the retina (arrow).
Scale bars are labeled for each row. See also Figure S6.
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Figure 7. Arrest of Lumen Formation and Excess
of Cytosolic Vacuoles in b1-Deleted Endothelial
Cells
(A) Semithin (left) and electron microscopy (right) analyses
of luminal occlusion in E15.5 b1f/f; Cre+ animals demon-
strates accumulation of multiple vesicles/vacuoles within
the cell cytoplasm (arrows).
(B) Evaluation of Rab7 (red) in the context of b1 integrin
(green) demonstrates Rab7 in the basal aspect of the
endothelium and at the SMC/EC junction with b1 integrin
(yellow), but minimal expression within the endothelial
layer (arrowhead). Upon b1 deletion, a dramatic increase
of Rab7 expression in b1-ablated ECs was noted (right;
arrowheads), with some maintenance of coexpression
with b1 integrin in the SMC layer (arrow).
(C) Schema depicts a working model of the cascade of
events that drive lumen formation. Activation of b1 integrin
instructs Par3 expression, which then allows for polariza-
tion of the endothelium. Vesicular fusion to the apical cell
membrane results in redistribution of junctional and
adhesion proteins (red; arrows), change in cell shape
from cuboidal to squamous, and acquisition of a vascular
lumen.
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b1 Integrin and Endothelial Polaritypresence of lumen. EphB4 IHC was conducted on a subset of sequential
slides to confirm venous versus arterial identity. A total of 250 arteries and
veins and 620 capillaries were counted from five independent littermate pairs
of b1f/f; Cre+ and b1f/f; Cre embryos.
b Integrin Antibody Blockade
Mice were anesthetized with isofluorane (Abbott Laboratories). For pups,
eyelids were first pierced under sterile conditions with an insulin syringe (BD
Pharmingen), followed by intravitreal injection of 1–2 ml of blocking antibody
or isotype control with the aid of pulled glass micropipets and a micromanipu-
lator; contralateral eye served as a noninjected control (3–4 ml used for adults).
Low-endotoxin blocking antibodies for b1 and b3 integrins and isotypes
(BD Pharmingen) were used at 1 mg/ml dilution.
Par3 Lentivirus
The entire 1333 nt open reading frame of mouse Par3 isoform 3 (NCBI refer-
ence sequence NP_296369) (see nomenclature in Supplemental Information)
was fused to a triple-flag tag (MADYKDHDGDYKDHDIDYKDDDDKGTSLYK
KAG) to generate 33Flag_mPar3 (plasmids were fully sequenced in both
orientations) and then cloned into the multiple cloning site of the lentiviral entry50 Developmental Cell 18, 39–51, January 19, 2010 ª2010 Elsevier Inc.plasmid pRRL-sin VECADivs NLS GFP-cPPT. Replica-
tion-deficient lentivirus directing expression of pRRL-sin
VECADivs_33Flag_mPar3-cPPT was then generated by
the UCLA Vector Core Facility.
Postnatal Induction of b1 Integrin Deletion
and Retina Manipulations
Mice were fed or injected (intragastrically) with 0.1–0.2 mg
(10–20 ml) of tamoxifen (MP Biomedicals) prepared as
described (Monvoisin et al., 2006) every other day from
P2 to P7. Controls included Cre mice also fed with
tamoxifen, andb1-ablatedmice fedor injectedwith vehicle
(sunflower oil). The amount of deletion was quantified by
counting b-gal-positive cells (nuclei of positive cells as
compared to total nuclei) in the abdominal muscles of the
respective mice. Purification of retinal endothelial cells
was accomplished by immunobeads (see Supplemental
Experimental Procedures for a full protocol).
Delivery of lentiviral proteins was accomplished by
intravitreal injection of 0.5–1.0 ml of 109 viral particles
(see antibody blockade above) and evaluation 48 hr later.
Injection of the Par3 or empty virus did not provoke anymajor infections or macroscopic alterations during that time period. The
mice appeared to respond to light and visual cues 1 day after the procedure.
Western Blotting
Isolatedmouse tissues or cells were placed in lysis buffer, loaded onto 8%acryl-
amide gels, and probed with Par3 (Upstate Biotechnology), tubulin (Sigma),
GAPDH (Chemicon) Cre-recombinase (Abcam), or b1 integrin (Chemicon). See
Supplemental Experimental Procedures for full protocol and antibody dilutions.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
online at doi:10.1016/j.devcel.2009.12.006.
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